Chemotherapy for breast cancer often shuts down ovarian function, causing estrogen levels to drop sharply and menstrual periods to stop in most women.
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
A systematic review could quantify the pooled prevalence of chemotherapy-induced amenorrhea across different regimens and age groups, identifying which agents are most gonadotoxic.
A systematic review and meta-analysis of all prospective studies reporting amenorrhea rates and serum estradiol levels in premenopausal breast cancer patients receiving chemotherapy, stratified by agent (e.g., cyclophosphamide, doxorubicin), age, and baseline ovarian reserve, including at least 20 studies with >5,000 total participants.
An RCT could determine whether specific chemotherapy regimens cause greater declines in estradiol than others, controlling for age and baseline hormone levels.
A multicenter RCT of 400 premenopausal breast cancer patients randomized to receive CMF versus AC versus taxane-based chemotherapy, measuring serum estradiol, FSH, and LH at baseline, mid-treatment, and 6 months post-treatment, with ovarian ultrasound and anti-Müllerian hormone as secondary endpoints.
A prospective cohort could confirm the temporal relationship between chemotherapy exposure and estradiol decline, adjusting for age and BMI.
A prospective cohort of 500 premenopausal breast cancer patients, with monthly estradiol measurements from diagnosis through 12 months post-chemotherapy, stratified by age (<35, 35–45, >45), chemotherapy regimen, and BMI, to model the rate and persistence of ovarian suppression.
A case-control study could identify whether women who develop persistent amenorrhea differ in baseline ovarian reserve or genetic markers compared to those who resume menstruation.
A matched case-control study comparing 100 women with persistent amenorrhea (>12 months post-chemotherapy) to 100 who resumed menses, assessing baseline AMH, FSH, and polymorphisms in drug metabolism genes (e.g., CYP2D6, GSTP1).
A cross-sectional study could estimate the prevalence of low estradiol among breast cancer survivors who received chemotherapy, but cannot determine causality.
A national survey of 3,000 breast cancer survivors, measuring current estradiol levels and asking whether they had chemotherapy and whether their periods returned, adjusting for age and time since treatment.